Malignant transformation is characterized by alterations in the normal properties of cell growth, adhesion, motility and shape. The multistep nature of this process is now well defined in a number of systems, and it has been established that genetic changes in specific genes are responsible for both positive and negative contributions to that process. Analysis of the genes involved has identified those which act positively to induce aspects of the transformed state (oncogenes) and, more recently, has led to the identification of those which act to block or suppress the malignant phenotype, the so-called tumor suppressor genes (24) . The importance of these genes in maintaining the normal phenotype was first implicated by the fact that in many human tumors, their functions have been lost as a consequence of deletion, rearrangement, or mutations of both alleles; indeed, the best-characterized members of this group, represented by Rb, p53, WTI, and DCC, were first identified and isolated following pedigree and genetic analyses (34) . The frequent physical or functional loss of these tumor suppressor genes in specific human malignancies was strong evidence that these changes contribute to the development of the neoplastic phenotype.
Loss of function of a particular gene may occur by a variety of mechanisms, including the repression of its expression at the RNA level, and a large number of genes whose expression is repressed either in tumors or in cells transformed by positively acting oncogenes, such as v-ras, v-src, and the simian virus 40 T-antigen gene, have been identified. This group includes genes encoding the retinoic acid receptor (20) , ␣-actinin (13), maspin (44) , interferon regulatory factor I (19) , and tropomyosin (31) as well as the DAN, 322, and rrg genes (8, 26, 28) . Several of these were identified by subtractive hybridization or differential display techniques, which allowed the identification of RNA species whose expression was reduced in transformed cells. In gene transfer experiments, these genes exhibited tumor-suppressive and cell growth arrest activities, leading to the hypothesis that the reduced expression or function of certain genes was required for the expression of the transformed phenotype.
We previously reported the characterization of a flat (nontransformed) revertant cell line, F-1, which was isolated from rat fibroblasts (DTM) transformed by the serine/threonine kinase oncogene mos (41) . F-1 cells express high levels of v-mosspecific RNA and kinase activity but fail to express character-istic transformed properties, including colony formation in soft agar and tumor formation in nude mice. Moreover, the revertants are resistant to retransformation by v-mos and v-raf, while they can be efficiently transformed by v-ras and, with a somewhat lower efficiency, v-src. The reversion and resistance to retransformation correlated with the failure of the serine/ threonine kinase oncogenes v-mos and v-raf to activate the mitogen-activated protein (MAP) kinase pathway due to their inability to activate MEK-1 or MEK-2, the immediate upstream activators of MAP kinase.
Since levels of MEK and MAP kinase were not changed in the revertant cells, and since growth factors and ras activated MEK and the MAP kinase cascade normally, our results suggested that the reversion could be the result of mutations affecting the expression or function of genes which contribute to the activation of MEK by v-mos or v-raf or could result from the expression in the revertant cells of genes which block this activation and which are down-regulated in DTM and other transformed cells. In an attempt to identify such transcriptional changes, we used differential display analysis to compare the expression of RNA in transformed and revertant cells. In this report, we describe the identification and characterization of a novel cDNA, designated drm (down-regulated in v-mostransformed cells), which is expressed in the F-1 revertant and normal parental rat fibroblasts but is down-regulated in rat fibroblasts transformed by several retroviral oncogenes. The drm cDNA shows no significant homologies to known genes in DNA databases and contains an open reading frame (ORF) capable of encoding an 184-amino-acid, cysteine-rich protein with a calculated molecular weight of 20,682. Regions of the drm protein show significant sequence homologies with the rat and human DAN (NO3) gene products (10, (28) (29) (30) , which have been shown to possess tumor-and growth-suppressing activities. The drm gene encodes a 20.7-kDa protein recognized by a specific antiserum in phenotypically normal rat cells. This protein was not detected in v-mos-transformed cells. Analysis of RNA from multiple tissues of the rat and in situ hybridization experiments in adult rats indicate that drm expression is regulated in a tissue-specific manner. In situ analysis also indicated that drm RNA is predominantly expressed in terminally differentiated, nondividing cells, such as neurons, type 1 cells of the lung, and goblet cells of the intestine.
Transfection analysis demonstrates that drm overexpression in normal rat fibroblasts blocks cell proliferation, while cotransfection with the ras oncogene reverses this inhibition. Furthermore, cells overexpressing drm and conditionally transformed with v-mos-expressing Moloney murine sarcoma virus (MSV) rapidly undergo apoptosis when shifted to the nonpermissive temperature. These results suggest that drm represents a newly identified gene which is likely to play a role in cell growth and tissue-specific differentiation.
MATERIALS AND METHODS
Cell culture. The REF-1, DTM, F-1, and ST33c rat cell lines have previously been described (40) (41) (42) . DTM and ST33c cell lines were maintained at 34°C in Dulbecco modified Eagle medium (Gibco) with 5% fetal calf serum; REF-1, as well as REF-1 transformed by different oncogenes, was grown at 37°C in Dulbecco modified Eagle medium (Gibco) with 5 or 10% fetal calf serum.
DNA and RNA analyses. High-molecular-weight DNA was purified by standard procedures (15) and analyzed by Southern blotting (35) . Total RNA was extracted from culture cells by RNAzolB (Tel-Test, Inc., Friendswood, Tex.) (7), and 10 g was used per lane in Northern analysis. Filters were prehybridized and hybridized at 42°C for 18 to 20 h in 5ϫ SSPE (1ϫ SSPE is 0.18 M NaCl, 10 mM NaH 2 PO 4 , and 1 mM Na 2 EDTA [pH 7.4]) containing 10ϫ Denhardt's solution (9) , 2% sodium dodecyl sulfate (SDS), 50% formamide, and 100 g of heatdenatured salmon sperm DNA per ml. The filters were washed sequentially in 2ϫ SSC (1ϫ SSC is 0.15 M NaCl plus 0.015 M sodium citrate)-0.05% SDS at room temperature for 30 min and in 0.1ϫ SSC-0.1% SDS at 50°C for 40 min.
Autoradiography was for 2 to 4 days at Ϫ70°C with an intensifying screen. Poly(A) ϩ was isolated by using a Fast Track mRNA isolation kit (Invitrogen) as specified by the manufacturer. Multitissue Northern blotting (Clontech) was done as specified by the manufacturer.
The murine recombinant retrovirus expressing v-src was a generous gift of S. M. Anderson. The vector expressing activated ras is pEJ-ras (38) containing the Val 12 -mutated fragments of human c-ras in pBR322. Identification and isolation of drm cDNA. mRNAs expressed differentially in DTM and F-1 cells were displayed as described by Liang and Pardee (25) . First-strand cDNAs were synthesized on 1.5 g of polyadenylated RNA extracted from either cell line, using a cDNA cycle kit for reverse transcription-PCR (Invitrogen) and specific primers T12VA and T12VC (V is either A, C, or G). cDNAs were then amplified by PCR using [␣- 35 S]dATP and combinations of 3Ј specific primers and arbitrary 5Ј primers (AGCCAGCGAA, GACCGCTTGT, AGGTGACCGT, GGTACTCCAC, and GTTGCGATCC). PCR products were separated on a 6% polyacrylamide gel and visualized by autoradiography.
Screening of a cDNA library. An oligo(dT)-primed cDNA library of rat embryo fibroblasts constructed in the ZAP XR vector was screened with the 691-bp drm cDNA isolated from F-1 mRNA by the differential display technique as described previously (35) . Three independent clones (Cl3ZAP, Cl7ZAP, and Cl10ZAP) were isolated and further analyzed. 5Ј sequences of the Cl7ZAP absent from the other clones were used as probes to screen a rat kidney 5Ј-stretch gt11 cDNA library (Clontech). Two clones (Cl7gt and Cl10gt) were isolated, further amplified, and analyzed. cDNA clones were sequenced on both strands by the dideoxy-chain termination method using a T7 sequencing kit (Pharmacia Biotech) (36) . Portions of the sequencing data were compiled and analyzed by using the University of Wisconsin Genetics Computer Group package (11) .
Protein analysis. (i) In vitro transcription and translation. The 2.1-kb EcoRI fragment of Cl10gt and the BamHI/KpnI fragment from this insert, both containing the putative drm coding region, were inserted into the Bluescript KS vector. Plasmid DNAs were transcribed and translated by using the TNT T7 and T3 reticulocyte lysate system (Promega) with L-[
35 S]cysteine (1, 200 Ci/mmol; Amersham). Translation products were separated by SDS-polyacrylamide gel electrophoresis (PAGE) and processed for fluorography. T7 polymerase produces a sense message, while T3 produces an antisense product. Luciferase DNA was used as a positive control.
(ii) Construction of a tagged drm protein expression vector. The coding region of drm cDNA was fused in frame at its 3Ј end with the DNA fragment encoding the nine-residue epitope of influenza virus hemagglutinin (HA1) by PCR. The primers used were 5Ј (5Ј-CCGCTCGAGGTGACAGAATGAATCGC-3Ј) and 3Ј (5Ј-CCCGTTAACTTAGGCGTAGTCGGGCACGTCGTAGGGGTAATC CAAGTCGAT-3Ј). The 5Ј primer introduces an XhoI restriction site, while the 3Ј primer removes the stop codon from the drm and introduces another one downstream from the inserted HA1 sequence. It also introduces an HpaI site downstream from the stop codon. The PCR product was digested with XhoI and HpaI and inserted into the pSVL expression vector (39) between the XhoI and SmaI sites.
(iii) Preparation and characterization of antibodies. Two peptides based on the predicted sequence of drm protein were selected to raise rabbit polyclonal antibodies. An N-terminal cysteine residue was added to the first peptide (peptide 990), which corresponds to amino acids 79 to 92, to enable coupling of the peptide to keyhole limpet hemocyanin carrier protein prior to immunization. The second peptide, 987, corresponding to amino acids 158 to 172, was coupled to the carrier protein through a natural cysteine residue on its N-terminal end. The polyclonal antipeptide antibody 990 gave the strongest immune response and was the only one used in this study.
(iv) Immunoprecipitation and Western blotting. Either cell lysates prepared under denaturing conditions were first immunoprecipitated with drm-specific antiserum 990 or anti-HA1 monoclonal antibody (Babco), followed by separation on SDS-PAGE and Western blotting, or total lysates were analyzed by SDS-PAGE and Western blotting.
For immunoblotting, proteins were electrophoretically transferred to nitrocellulose at 60 mA for 2 h. Filters were incubated first with the appropriate primary antibody and then with horseradish peroxidase-labeled secondary antibodies (Amersham). Antibodies were detected by using the ECL detection system (Amersham) or the Super Signal CL-HRP Substrate system (Pierce) and visualized by using Kodak XAR-5 X-ray film.
Western blots were stripped for reprobing with other primary antibodies as specified by the manufacturer (Amersham).
Transfection of drm expression vectors. For stable transfection experiments, cDNA containing the full-length drm ORF was inserted into the BamHI and KpnI restriction sites of the pMEXneo expression vector (21) . In this construct, drm and the neo-selectable marker were under the control of a murine leukemia virus long terminal repeat and a simian virus 40 promoter, respectively. For colony formation assays, 5 ϫ 10 5 cells were overlaid with a mixture consisting of 5 g of pMEXdrm or pMEX and 30 l of DOTAP (Boehringer Mannheim). After 6 h, this mixture was replaced with regular medium and the cultures were maintained for another 48 h. Cells were then split 1:3 and grown in the presence of G418 (effective concentration, 400 g/ml; Life Technologies) for 2 weeks, and colonies resistant to G418 were counted and isolated. Growth temperatures for transfected cells were as follows: for REF-1 and CHO, 37°C; for DTM, 34°C; and for ST33c, 34 and 39°C. Transient transfections of Cos-7 cells were performed by using the pSVL vector expressing a HA1-tagged drm and LipofectAMINE (Life Technologies, Gaithersburg, Md.) as specified by the manufacturer.
In situ hybridization. Tissues from Sprague-Dawley rats were processed and analyzed by in situ hybridization as described by Sassoon and Rosenthal (37) . A nonradioactive riboprobe containing 1.9 kb of the 3Ј end of drm was generated by using a digoxigenin RNA labeling kit (SP6/T7; Boehringer Mannheim), and the concentration of the labeled probe was determined by using a SIG nucleic acid detection kit (Boehringer Mannheim). Detection was performed by using an antidigoxigenin antibody conjugated with alkaline phosphatase (nucleic acid detection kit; Boehringer Mannheim). Sections were counterstained with methyl green (1%) and mounted in aqueous mounting medium (Signet Laboratories). Analysis was performed on a Nikon Labophot 2 microscope.
Analysis of apoptosis. ST33c cells were transfected with the control vector or with the vector containing drm at 34°C, and pools of G418-resistant colonies were selected, expanded, and analyzed for expression of drm-specific mRNA. ST33c cells expressing drm were shifted to 39°C for 24 h, and cells were fixed in 3.7% formaldehyde in phosphate-buffered saline (10 min, room temperature), washed three times, stained in 4Ј,6-diamidino-2-phenylindole (DAPI) (10 min, room temperature), and examined with a Nikon inverted microscope under UV illumination. DNA fragmentation analysis was performed as previously described (1) .
Nucleotide sequence accession number. The drm sequence has been assigned GenBank/EMBL accession no. Y10019.
RESULTS
Identification of an mRNA expressed in revertant cells but repressed in v-mos-transformed rat fibroblasts. To identify genes expressed in F-1 revertant cells but not in v-mos-transformed parental cells (DTM cells), we performed differential display analysis (25) using oligo(dT)-selected RNA isolated from rapidly growing DTM and F-1 cells. Eight cDNAs differing in intensity between DTM and F-1 mRNAs were identified and used to probe Northern blots containing poly(A) ϩ RNA from DTM and F-1 cells. Only one exhibited differential mRNA expression; this probe detected a 4.4-kb RNA expressed in F-1 cells but absent in DTM cells (Fig. 1A , lanes 2 and 3). Analysis of this cDNA, designated drm, revealed a 691-bp sequence, which included a consensus polyadenylation signal (AATAAA) located 20 bp upstream from the poly(A) tail, as well as the 5Ј and 3Ј primers used for PCR. A search of nucleotide sequences compiled in the GenBank database showed no significant similarities to known genes.
Repression of drm mRNA expression following cell transformation. To establish a correlation between repression of drm gene expression and the transformed cell phenotype, we analyzed the hybridization of drm cDNA to RNA from normal and transformed REF-1 cells. We found that drm was expressed at similar levels in REF-1 and revertant F-1 cells, but its expression was completely repressed in REF-1 cells transformed by the v-ras, v-raf, v-src, and v-fos oncogenes (Fig. 1A) . These results demonstrated that repression of drm expression was not restricted to transformation induced by v-mos.
Since the initial identification of drm was based on its expression in the F-1 revertant, and we had previously shown that F-1 cells could be transformed by v-ras and v-src, we analyzed the effect of expression of these oncogenes in F-1 cells on drm expression. F-1 cells expressing and transformed by v-ras and v-src did not contain drm transcripts detectable by Northern blot analysis (Fig. 1B, lanes 2 and 3) ; in contrast, F-1 cells infected with the v-mos-expressing MSV-124 show levels of drm RNA essentially identical to those in uninfected F-1 cells or REF-1 parental cells (Fig. 1B, lane 4) . Since we had previously shown that superinfection of F-1 cells with additional copies of v-mos did not induce transformation (41), these results are consistent with the hypothesis that drm expression is down-regulated following oncogene-mediated transformation.
To further analyze the correlation between drm expression and the transformed phenotype, we used REF-1 cells transformed by a temperature-sensitive (ts) isolate of Moloney MSV (ts110) (3). These cells (ST33c) are transformed at 34°C but express a phenotypically normal, nontransformed phenotype at 39°C (42) . Analysis of RNA extracted from cells maintained at both temperatures indicated that drm RNA was synthesized at 39°C in the absence of the v-mos protein and was markedly decreased at 34°C (Fig. 1C, lanes 3 and 4) . drm is a novel gene. To fully characterize the drm gene and its product, we screened rat fibroblast and rat kidney cDNA libraries and isolated five independent overlapping cDNA clones, which covered ϳ3,820 bp of drm mRNA (Fig. 2) . Southern blot analysis (data not shown) indicated that the drm sequence is derived from a single gene spanning at least 12 kb and is not rearranged either in DTM, which does not express drm, or in the F1 revertant.
The cloned cDNA of 3,820 nucleotides is shorter than the RNA identified in REF-1 cells, suggesting that the isolated clone may not include the entire drm mRNA sequence. However, this cDNA does contain a single long ORF beginning at nucleotide 130 and terminating with an in-frame stop codon at nucleotide 693. Translation is predicted to start at the first in-frame methionine at nucleotide 139 within a favorable translation initiation context (A at Ϫ3, C at Ϫ4, G at Ϫ6, and A at ϩ4) (22, 23) . Thus, the characterized drm cDNA consists of 138 bp of 5Ј untranslated sequence (65% GC), a 552-bp coding region, and 3,130 bp of 3Ј untranslated sequence containing a consensus polyadenylation signal, AATAAA, located 21 nucleotides upstream from the poly(A) tail.
The major ORF contained in the drm cDNA would be predicted to encode a 184-amino-acid polypeptide with a calculated molecular weight of 20,682. The presumptive drm gene product is highly basic (7.61% arginine, 8.7% lysine, and 2.17% histidine), with the NH 2 -terminal half containing a leucine-rich hydrophobic domain located between amino acids 4 and 24, whereas the carboxy-terminal moiety is characterized by the presence of nine cysteines. The presence of an amino-terminal Comparison of the drm amino acid sequence to entries in the GenBank and EMBL databases by using FASTA program showed that the drm protein exhibits an overall similarity of 30% with the rat and human DAN gene products, which express tumor-suppressive properties (28, 29) . Using the BLAST program, we detected a 52% similarity between the carboxyterminal cysteine-rich half of drm, the central region of the DAN protein, and the carboxy-terminal region of the Xenopus protein Cerberus (CER), a head-inducing secreted factor expressed in the anterior endoderm of Spemann's organizer (4) . Further analysis also revealed similarity to the carboxy-terminal cysteine-rich end of the human intestinal mucin MUC2 (16) (Fig. 3) . Interestingly, the nine cysteines of the drm are also present in DAN, CER, and MUC2 proteins at similar amino acid intervals. This alignment generated the cysteine motif CX 13 CX 8-9 CX 3 CX 14-18 CX 2 CX 13 CX 15-18 CXC. Within this motif, several amino acids are conserved, suggesting that proteins containing this domain could be members of a related family.
Characterization of the drm gene product. In vitro transcription and translation of the ORF-containing 2.1-kb EcoRI fragment and 730-bp BamHI/KpnI fragment of drm cDNA confirmed that the presumptive ORF could express a protein of approximately the expected size (data not shown). To further characterize the drm product, we generated an antipeptide polyclonal rabbit antibody directed against amino acids 79 to 92 of the rat drm protein. To assess the specificity of the antiserum, we constructed an expression vector synthesizing an HA1 epitope-tagged drm protein by introducing a DNA fragment encoding the HA1 epitope at the 3Ј end of the coding region. The pSVL expression vector containing this fusion was used to transfect Cos-7 cells; cell lysates were prepared 48 h later, immunoblotted on a nitrocellulose filter, and incubated with the drm antiserum. We detected a band with a predicted molecular mass of ϳ21.4 kDa (Fig. 4A, lane 2) , and the same band was revealed with the monoclonal antibody against the HA1 tag (Fig. 4A, lane 6) . It was not detected when lysates were exposed to antiserum 990 preincubated with peptide against which this antiserum was raised (Fig. 4A, lane 4) or in lysates of cells transfected with an empty vector (Fig. 4A, lane  1) . A protein of the same molecular mass was detected in HA1-drm-transfected Cos-7 lysates immunoprecipitated with antiserum 990 and blotted with anti-HA1 serum, and this precipitation could be blocked by the homologous 990 peptide (data not shown).
To identify the endogenous drm protein, we analyzed total lysates from various cells by Western blotting (Fig. 4B) . We detected low levels of a 20.7-kDa protein in primary embryonic rat fibroblasts and in REF-1 cells (Fig. 4B) . Analysis of drm protein expression in ST33c cells, conditionally transformed by v-mos, showed good correlation with drm-specific RNA expression. The protein was not detected in lysates of transformed cells at 34°C (Fig. 4B ) but could be seen in cell lysates prepared 48 h after the cultures were shifted to the nonpermissive temperature (Fig. 4B) . We could not detect drm protein in lysates of v-mos-transformed DTM cells (Fig. 4B) .
drm RNA is expressed in a tissue-specific fashion in adult rats. To further characterize the drm gene and its possible function, we examined the expression pattern of drm in rodent tissues. Northern blot analysis of poly(A) ϩ RNA extracted from adult rat tissues (Sprague-Dawley) showed that the drm gene was expressed in the brain, kidney, spleen, testis, and lung but not in the heart and skeletal muscle (Fig. 5) . Highest levels 
FIG. 5. Expression of the drm gene in normal rat tissues. Multitissue Northern blot analysis of poly(A)
ϩ RNA from rat tissues. A multitissue poly(A) ϩ RNA Northern blot (Clontech) from adult rat tissues was hybridized with a 32 P-labeled 1.9-kb drm cDNA fragment. After the initial 3-day exposure, the probe was stripped off and the blot was rehybridized with a human ␤-actin probe and exposed to X-ray film for 20 h. The position of drm is indicated as a 4.4-kb transcript.
were seen in the kidney, testis, brain, and spleen; levels in the liver and lung were significantly lower.
To investigate whether drm expression was specific for any particular cell type, we analyzed tissues from the same strain of rat by in situ hybridization using sense and antisense drm riboprobes (Fig. 6) . In situ expression patterns in general correlated well with the Northern analysis, but interestingly, we found that drm RNA appeared to be predominantly expressed in differentiated cells (e.g., neurons in brain, type 1 cells in lung, and goblet cells in intestine). In all cases, the control sense probe showed no detectable hybridization (Fig. 6C) .
The brain exhibited ubiquitous expression of drm RNA. High levels of drm expression were found in both neurons and glial cells of the brain cortex; in the cerebellum, drm RNA was strongly expressed in all cells of molecular and granular layers. Its expression was significantly weaker in Purkinje cells (Fig.  6A) .
In the kidney, drm RNA was found in epithelial cells of the proximal and distal tubules in the cortex, medullae, and papillae. Very strong signals appeared to be localized in the nuclei of the epithelial cells (Fig. 6A) .
In the small and large intestine, the drm gene was predominantly detected in goblet cells, and specifically in the most differentiated goblet cells (on the tip of the villi in the small intestine and the base and neck of the crypt in the large intestine) (Fig. 6A) . However, some goblet cells in the crypt of the small intestine were also found to be positive for drm expression.
In the lung, drm expression was localized to the nuclei of type 1 epithelial cells lining the alveoli (Fig. 6A) . Type 1 cells are known to be terminally differentiated from their precursor type 2 cells (6). drm was not expressed in every type 1 cell, which could indicate a possible correlation of drm expression with the stage of cell differentiation. A few endothelial cells of the airways and a number of macrophages also expressed drm RNA; in the spleen, drm RNA was detected only in megakaryocytes. In agreement with the results of Northern blot analysis, we could not detect drm hybridization in the liver, heart, and skeletal muscle (data not shown).
drm blocks colony formation by normal but not transformed cells. To determine the biological effect of drm overexpression in vivo, a portion of the drm cDNA containing the full-length ORF was inserted into the neo-containing pMEX expression vector (21) . This construct, as well as the empty vector, was introduced into REF-1 and DTM cells, and G418-resistant colonies were counted after 2 to 3 weeks. Our results indicated that colony formation was inhibited 30-fold when REF-1 cells were transfected with the drm expression vector (Fig. 7) . mos- (Fig. 8A, lanes 3 to 6) , suggesting that survival may select for cells expressing low levels of drm. In contrast, DTM cells, which showed no inhibition of colony formation, exhibited high levels of exogenous drm expression (Fig. 8A, lane 1) . In some cases, expression of endogenous drm RNA was also increased in DTM cells expressing exogenous drm, suggesting a possible autoregulation loop of drm expression.
Since oncogene-transformed stable cell lines had shown down-regulation of drm expression (see above), we further investigated the interactions between transforming oncogenes and drm by cotransfecting REF-1 and CHO cells with drm and the activated (38) ras oncogene. Consistent with our previous results with DTM cells, cotransfection of drm with the ras oncogene did not suppress morphological transformation. However, cotransfection of ras with drm reversed the drmdependent inhibition of colony formation both in REF-1 cells (84% of the control [ Fig. 7] ) and in CHO cells (data not shown). The level of exogenous drm RNA in five of six G418-resistant clones cotransfected with pMEXdrm and ras was increased (Fig. 8B) . These data are consistent with the hypothesis that high levels of drm inhibit the growth or viability of normal cells but that transformed cells are resistant to this inhibitory effect.
Conditionally transformed cells expressing exogenous drm undergo apoptosis at the nonpermissive temperature. Since transfection of nontransformed rat and hamster cells with drm expression vectors leads to the inhibition of cell growth, we could not obtain stable cell lines expressing high levels of drm for molecular and biological analysis. To overcome this problem, we used conditionally transformed ST33c cells to investigate the effects of drm overexpression. As shown in Fig. 9A , when v-mos is functional (34°C) and ST33c cells are transformed, transfection of the pMEXdrm vector does not affect the efficiency of colony formation in comparison to the control vector. These results are consistent with our data for DTM cells and for REF-1 cells cotransfected with pMEXdrm and ras (Fig. 7) , showing that the presence of transforming oncogene blocks the inhibitory effect of drm. In contrast, at 39°C the percentage of colonies that survived following pMEXdrm transfection was significantly lower than that observed in control vector-transfected ST33c cells (Fig. 9A) .
To analyze how drm overexpression blocks cell growth and colony formation, G418-resistant colonies of transfected ST33c cells were isolated at 34°C and tested for the expression of drm. Pools of G418-resistant cells expressed elevated levels of drm RNA similar to those seen in transfected DTM (Fig. 8A, lane  1) or ras-transformed (Fig. 8B) cells. These transfected pools grew like the parental ST33c cells at 34°C, when v-mos is expressed, but rapidly lost viability after a shift to 39°C, and colony-forming ability was significantly reduced. This finding is consistent with the fact that, as previously shown, v-mos is not expressed in these cells at 39°C and thus cannot neutralize the effects of the high level of exogenous drm in these cells. The morphological changes seen in these cells at 39°C, including cell shrinkage, cell membrane blebbing, and loss of cell-cell contact and adhesion to the substrate, resemble those of cells undergoing apoptosis. Furthermore, drm-expressing ST33c cells exhibited nuclear fragmentation and condensation within 24 h of a shift to 39°C, while no such fragmented nuclei were observed in these cells cultured at 34°C or in REF-1 cells cultured at either 34 or 39°C (Fig. 9B) . We observed that 15 to 30% of the ST33c cells expressing drm at 39°C exhibited fragmented, condensed nuclei, while only 5 to 6% of the control ST33c cells manifested similar changes following a shift to 39°C. DTM cells transfected with drm and containing two copies of v-mos (ts and wild-type v-mos) also showed 5 to 7% fragmented nuclei at 39°C, which could represent the background level for ts v-mos-transformed cells shifted to 39°C. Apoptosis of drm-expressing ST33c cells at 39°C was also confirmed by agarose gel electrophoresis of genomic DNA, which showed significant fragmentation only in the cells shifted to 39°C (Fig. 9C) . Furthermore, the proportion of cells undergoing apoptosis was seen to correlate with the level of drm expression in a series of individual clones of ST33c cells trans- fected with drm (data not shown). Taken together, our data suggest that cells expressing high levels of drm undergo apoptotic death in the absence of oncogene-induced transformation.
DISCUSSION
We have used differential display analysis of RNA to screen for genes either up-or down-regulated in a revertant (F-1) of mos oncogene-transformed rat embryo fibroblast cells (DTM cells). We have identified a gene, drm, whose expression was high in the revertant cell line and REF-1, the nontransformed parent of the DTM cell line, but was not detectable in DTM cells or in REF-1 cells transformed by either ras or src. We have cloned 3.8 kb of the drm cDNA which can encode a 184-amino-acid protein and shown that introduction of a drugselectable construct containing this sequence into nontransformed cells significantly reduced their colony-forming ability. In contrast, cotransfection of normal cells with drm and ras, or transfection of drm into stably transformed cells, generated colonies with efficiencies essentially equivalent to those seen with vector controls. Cells conditionally transformed by v-mos and expressing high levels of transfected drm grew stably at the permissive temperature but rapidly underwent apoptosis when cells were shifted to the nonpermissive temperature. Furthermore, the expression pattern of drm seen upon in situ hybridization in rat tissues suggested that the drm expression occurs in nonproliferating, terminally differentiated cells (Table 1) .
Taken together, these results demonstrate that drm represents a previously unidentified gene and suggest that drm functions in the regulation of cell growth or viability.
The drm cDNA contains a 552-bp ORF capable of encoding a 20.7-kDa protein, and an antibody raised against a peptide contained in this predicted sequence recognizes a protein of similar size in cells expressing the drm message, including primary rat fibroblasts, REF- This domain contains a well-conserved array of nine cysteines, with only small differences of spacing between cysteines 4 and 5 and between cysteines 7 and 8. The fact that this motif is found in only four proteins suggests that it is highly specific and may represent a novel structural domain. It is also possible that these apparently unrelated proteins are derived from a common ancestral gene or interact with related or identical partners.
In addition, the homology between drm and DAN is interesting in view of the fact that drm was initially identified on the basis of its down-regulation in transformed cells, which was suggestive of a potential tumor-suppressing activity. Expression of drm RNA and protein correlated with the nontransformed phenotype in REF-1 and the F-1 revertant of mostransformed cells and was seen in conditionally transformed cells at the nonpermissive temperature. The observations that (i) drm expression was down-regulated by oncogenes, such as v-raf, v-mos, v-src, and v-ras, which are known to activate MAP kinase and (ii) drm is up-regulated in the F-1 revertant in which mos-dependent activation of MAP kinase is blocked suggest that drm may be regulated by the MAP kinase cascade. This is also consistent with our observation that transformation by activated MKK or v-fos, the viral homolog of fos and a known downstream target of the MAP kinase cascade, also down-regulated drm (data not shown), supporting the hypothesis that the MAP kinase cascade is involved in drm regulation. Several tumor suppressor genes are known to be down-regulated in response to transformation by specific oncogenes. In particular, DAN (28) is down-regulated by v-src, v-mos, and v-raf but not v-ras, while 322 (26) is down-regulated by v-src, v-ras, v-fos, and v-myc but not v-raf and v-mos. Drm, however, exhibited a unique regulation pattern which nevertheless is consistent with that seen in other transformation-sensitive genes.
Although analysis of the predicted drm peptide sequence failed to reveal its biological function, the results of in situ hybridization in normal rat tissue, together with the effects of introducing drm-expressing constructs into cells in culture, suggest a possible role for drm in the control or maintenance of cell growth and viability. We observed high levels of expression in terminally differentiated, nondividing cells of specific tissues of adult rat (Table 1) , such as goblet cells of the colon and the small intestine. Goblet cells, which have a unique morphology and can be easily identified, enter the proliferative zone of the crypt, differentiate as they migrate up the villus, and undergo apoptosis as they reach the top (14, 17) . The majority of drm expression is seen in goblet cells on the neck and top of the villus, corresponding to differentiated cells and cells undergoing apoptosis. Similarly, correlations between drm expression and differentiation were also seen in the lung, where the drm message was seen in the nuclei of type 1 cells, epithelial cells lining the alveoli which are known to be terminally differentiated from their precursor type 2 cells (6). Not every type 1 cell expresses drm, suggesting a possible correlation with the stage of differentiation, and significantly, we failed to detect drm expression in proliferating type 2 precursor cells. Similarly, drm expression in the brain was seen in terminally differentiated neurons, while in the kidney, drm RNA was detected in epithelial cells of the proximal and distal tubules, which are present in a differentiated state, with only 0.1% of these cells dividing at any given time (2, 32) . These findings are highly suggestive that in multiple rat tissues, drm expression is seen in terminally differentiated, nondividing cell populations.
This pattern seen in situ seems even more interesting in view of the fact that the introduction of drm expression constructs into normal REF-1 cells significantly reduced their colonyforming ability, indicating an effect on cell growth or viability. This inhibiting effect of drm in normal cells could be overcome by cotransfection with the ras oncogene, and no effect of drm transfection was seen in cells stably transformed with either v-mos or ras. While the precise mechanism of drm inhibition on REF-1 colony formation has not been determined, we were able to use cells conditionally transformed by v-mos to analyze the effects of drm overexpression on normal cell growth and viability. These cells, which expressed high levels of drm and proliferated normally at the permissive temperature, underwent apoptosis within 24 h following a shift to the nonpermissive temperature.
The results with cells conditionally expressing the v-mos oncogene suggest that the transforming function is able to inactivate or block the apoptotic response to drm. This type of protective effect in response to oncogene expression may be a common response, and it has been shown that src transformation involves the up-regulation of nr-13, a new member of the bcl family (12) which protects cells from apoptosis. Furthermore, studies of transformation by DNA tumor viruses showed that the 19-kDa adenovirus E1B transforming protein plays a direct role in the suppression of apoptosis induced by E1A and that its effects resemble those of the proto-oncogene product Bcl-2 (5, 27, 33, 43) . Alternatively, the level of drm expression in v-mos-and ras-transformed cells may be insufficient to interfere with cells in which proliferation is driven by these oncogenes. The experimental model allowing the conditional expression of the apoptotic response in transformed cells should prove useful in dissecting the mechanism of drm function in growth control and apoptosis.
Taken together, our in vitro and in vivo results suggest that high levels of drm expression lead to a loss of growth potential and/or apoptosis, which is normally associated with terminal differentiation, and that these effects can be mediated by interactions between drm and the proteins or genes involved in these processes. Experiments are in progress to investigate the effects of drm expression on the functions of genes known to be involved in growth control. Furthermore, our results demonstrating down-regulation of drm in cells transformed by dominant oncogenes suggest a possible role for drm in the oncogenic transformation of specific cell lineages. We hypothesize that oncogene expression in differentiating cells expressing or potentially expressing drm leads to drm down-regulation, in order to abrogate the apoptotic response and allow progression toward malignancy. Studies are in progress to determine if this model is consistent with analyses of specific human neoplasms.
